• 1. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Very long-chain fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Very long-chain fatty acids

Recent Advances in the Study of 9(Z),12(Z),15(Z),18(Z)-Tetracosatetraenoic acid (CAS: 3508-03-0)

The compound 9(Z),12(Z),15(Z),18(Z)-Tetracosatetraenoic acid (CAS: 3508-03-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This polyunsaturated fatty acid (PUFA) is structurally characterized by four cis double bonds at the 9th, 12th, 15th, and 18th positions, making it a subject of interest for its potential biological activities and therapeutic applications. Recent studies have explored its role in inflammation modulation, lipid metabolism, and its potential as a precursor for bioactive lipid mediators.

One of the key findings in recent research is the compound's involvement in the resolution of inflammation. Studies have demonstrated that 9(Z),12(Z),15(Z),18(Z)-Tetracosatetraenoic acid can be metabolized into specialized pro-resolving mediators (SPMs), which play a crucial role in the active termination of inflammatory responses. This discovery has significant implications for the development of novel anti-inflammatory therapies, particularly for chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

In addition to its anti-inflammatory properties, recent investigations have highlighted the compound's potential in modulating lipid metabolism. Research conducted on animal models has shown that supplementation with 9(Z),12(Z),15(Z),18(Z)-Tetracosatetraenoic acid can influence the expression of genes involved in fatty acid oxidation and lipid storage. These findings suggest a possible role for this PUFA in the management of metabolic disorders, including obesity and non-alcoholic fatty liver disease (NAFLD).

Another area of interest is the compound's structural similarity to other biologically active PUFAs, such as arachidonic acid and eicosapentaenoic acid (EPA). This similarity has led researchers to investigate its potential as a substrate for the synthesis of novel lipid mediators with unique biological activities. Preliminary studies have identified several metabolites of 9(Z),12(Z),15(Z),18(Z)-Tetracosatetraenoic acid that exhibit potent bioactivities, including vasodilation and platelet aggregation inhibition.

Despite these promising findings, challenges remain in the practical application of 9(Z),12(Z),15(Z),18(Z)-Tetracosatetraenoic acid. One of the primary hurdles is the compound's limited natural availability, which necessitates the development of efficient synthetic routes. Recent advances in organic synthesis have enabled the production of this PUFA in higher yields, paving the way for further pharmacological studies. Additionally, the stability of the compound under physiological conditions is an area of ongoing research, as oxidative degradation can compromise its bioactivity.

In conclusion, 9(Z),12(Z),15(Z),18(Z)-Tetracosatetraenoic acid (CAS: 3508-03-0) represents a promising candidate for further exploration in the fields of inflammation resolution, lipid metabolism, and drug development. Continued research into its biological mechanisms, synthetic accessibility, and therapeutic potential will be crucial for translating these findings into clinical applications. The compound's unique structural features and diverse bioactivities make it a valuable subject for future studies in chemical biology and pharmaceutical sciences.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)